In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

used in combination antiretroviral therapy, is effective and safe for heavily treatment-experienced patients with multidrug-resistant HIV. Data from the study were presented at the 2025 Conference ...

HIV commodities worth about Sh30 billion are lying at the Mombasa Road warehouses of the Mission for Essential Drugs & Supplies (MEDS), awaiting distribution, the NSDCC has said.The consignment ...

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.

Thanks to advances in the treatment of HIV with antiretroviral therapy ... including the challenges of analyzing paper charts (not electronic records), a lack of standardized diagnostic codes ...

a drug used to treat type 2 diabetes, could help deplete the viral reservoir and eliminate it entirely in people living with HIV who receive antiretroviral ... Potential Link Between DNA Markers ...

Without U.S. funding, distribution from the warehouse, which stocks all U.S. government-donated HIV medicine to Kenya, has ceased, leaving supplies of some drugs worryingly low, according to a ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

A child sits as nurse Sarah Mleli prepares to dispense antiretroviral ARV drugs used to prevent HIV from replicating, at the Nyumbani Children's Home, which cares for more than 100 children with ...